Effects of the Tricyclic Nucleoside 6-Amino-4-methyl-8-(-D-ribofuranosyl)-pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine on the Viability and Cell Cycle Distribution of L1210 Cells in Vitro

Cancer Research

Volumn 45, Issue , 1985, Pages 6355-6361

  Wotring, Linda L ^a   Passiatore, Joan E ^a   Townsend, Leroy B ^a   Hudson, Jerry L ^b   Roti, Joseph L Roti ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NUCLEOSIDE; RADIOISOTOPE; THYMIDINE H 3; TRICIRIBINE; UNCLASSIFIED DRUG;

ARTICLE; BLOOD AND HEMOPOIETIC SYSTEM; CELL CULTURE; CELL CYCLE S PHASE; DNA SYNTHESIS; DRUG EFFICACY; GROWTH INHIBITION; HEREDITY; IN VITRO STUDY; LEUKEMIA L 1210; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; DNA, NEOPLASM; LEUKEMIA L1210; MICE; MITOTIC INDEX; RIBONUCLEOSIDES;

EID: 0022370897     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bennett, L. L., Jr., Smithers, D., Hill, D. L., Rose, L. M., and Alexander, J. Biochemical properties of the nucleoside of 3-amino-1, 5-dihydro-5-methyl-1, 4, 5, 6, 8-pentaazaacenaphthylene (NSC-154020). Biochem. Pharmacol., 27: 233-241, 1978.
2. Bruchovsky, N., Owen, A. A., Becker, A. J., and Till, J. E. Effects of vinblastine on the proliferative capacity of L eels and their progress through the division cycle. Cancer Res., 25: 1232-1237, 1965.
3. Crabtree, G. W., Spremull, E. N., Weiman, M. C., Smith, D. E., Salvatore, J. R., Cumrnings, F. J., and Calabresi, P. Phase I clinical and pharmacokinetic study of tricyclic rnjcleoside-5ʹwmonophosphate (TCN-P; NSC280594). Proc. Am. Soc. Clin. Oncol. 2: 33, 1983.
4. Feun, L. G., Savaraj, N., Bodey, G. P., Lu, K., Yap, B. S., Ajani, J. A., Burgess, M. A., Benjamin, R. S., McKelvey, E., and Krakoff, I. Phase I study of tricyclic nucleoside phosphate using a five-day continuous infusion schedule. Cancer Res. 44: 3608-3612, 1984.
5. Mittelman, A., Casper, E. S., Godwin, T. A., Cassidy, C., and Young, C. W. Phase I study of tricyclic nucleoside phosphate. Cancer Treat. Rep., 67: 159-162. 1983.
6. Palmer, C. G., Uvengood, D., Warren, A. K., Simpson, P. J., and Johnson, I. S. The action of vincaleukoblastine on mitosis in vitro. Exp. Cell Res., 20: 198-201, 1960.
7. Passiatore, J. E., Wotring, L. L., and Townsend, L. B. Studies on the mechanism of cell death in L1210 cells treated with the tricyclic nucleoside, TCN. Proc. Am. Assoc. Cancer Res., 23: 213, 1982.
8. Phiips, H. J. Dye exclusion tests for cell viability. In: P. F. Kruse, Jr., and M, K. Patterson, Jr. (eds.), Tissue Culture Methods and Applications, pp. 406-408. New York: Academic Press, 1973.
9. Plagemann, P. G. W. Transport, phosphorylation, and toxicity of a tricyclic nucleoside in cultured Novikoff rat hepatoma cells and other ceM lines and release of its monophosphate by the ceHs. J. Natl. Cancer Inst., 57: 1283-1295, 1976.
10. Richardson, R., Powis, G., Rubin, J., Moertel, C., and Kovach, J. Phase I study of tricyclic nucleoside 5ʹ-phosphate (TCN-P) given on a dairy x 5 schedule. Proc. Am. Soc. Clin. Oncol., 2. 41, 1983.
11. Roti Roti, L. W., Roti Roti, J. L. and Towraend, L.B. Studies on the of cytotoxicity of the tricyclic nucleoside NSC-154020 in L1210 ceHs. Proc. Am. Assoc. Cancer Res., 19: 40, 1978.
12. SchHcher, R., Haas, C., Young, J., and Baker, L. Phase I evaluation and pharmacokinetics of tricyclic nucleoside 5ʹ-phosphate (TCN-P. NSC280594) in a weekly i. v. schedule. Proc. Am. Soc. CHn. Oncol., 2: 31, 1983.
13. Schram, K. H., and Townsend, L. B. The synthesis of 6-amino-4-methyl-8-(β-D-ribofuranosyl)-pyrrolo(4, 3, 2-delpynrndo[4, 5-c]pyridzine, a new tricyclic nucleoside. Tetrahedron Lett., 49: 4757-4760, 1971.
14. Schweinsberg, P. D., and Loo, T. L. Metabolic effects of the antitumor tricyclic nucleoside, 3-amino-1, 5-dihydro-5-methyl-1 -β-D-ribofuranosyl-1, 4, 5, 6, 8-pen-taazaacenaphthylene (TCN, NSC-154020). Proc. Am. Assoc. Cancer Res., 21: 33, 1980.
15. Schweinsberg, P. D., Smith, R. G., and Loo, T. L. Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020). Biochem. Pharmacol., 30. 2521-2526, 1981.
16. Townsend, L. B., Bhat, G. A., Chung, F. -L., Schram, K. H., Panzica, R. P., and Wotring, L. L. Synthesis, chemical reactivity, biological and chemotherapeutic activity of certain tricyclic nucleosides. INSERM Coloq., 81: 37-82. 1978.
17. Vmdetov, L. L. Flow microfluorometric analysis of nuclear DNA in ceHs from solid tumors and cell suspensions. Virchows Arch. Abt. B ZeHpathol., 24: 227-242, 1977.
18. Wotring, L. L., Crabtree, G. W., Edwards, N. L., Parks, R. E., Jr., and Townsend, L. B. Mechanism of activation of TCN-P as a prodrug form of TCN. Cancer Treat. Rep., in press, 1985.
19. Wotring, L. L., and Roti Roti, J. L. Thioguanine-induced S and G2 blocks and their significance to the mechanism of cytotoxicity. Cancer Res., 40: 1458-1462, 1980.
20. Wotring, L. L., and Townsend, L. B. Study of the cytotoxicity and metabolism of 4-aniinc-3-Carboxamido - 1 -(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine using inhibitors of adenosine kinase and adenosine deaminase. Cancer Res., 39: 3018-3023 1979.
21. Wotring, L. L., Townsend, L. B., Crabtree, G. W., and Parks, R. E., Jr. A possible role for ecto-5ʹ-nucleotidase in cytotoxicity and intracellular nucleotide formation from the tricyclic nudeoside-5ʹ-phosphate (TCN-P). Proc. Am. Assoc. Cancer Res., 22: 257, 1981.
22. Yataganas, X., and Clarkson, B. D. Flow microfluorometric analysis of cell killing with cytotoxic drugs. J. Histochem. Cytochem., 22: 651-659, 1974.
23. Yataganas, X., Mitomo, Y., Traganos, F., Strife, A., and Clarkson, B. D. Evaluation of a Feulgen-type reaction in suspension using flow microfluorimetry and a ceH separation technique, Acta Cytoi., 19: 71-78, 1975.